肾臟生物标记市场－全球产业规模、份额、趋势、机会及预测（按产品类型、技术、最终用户、地区和竞争格局划分，2021-2031年）

全球肾臟生物标记市场预计将从 2025 年的 14.1 亿美元成长到 2031 年的 21.5 亿美元，复合年增长率为 7.28%。

肾臟生物标记是可测量的生物学指标，可在血液、尿液或组织中检测到，对于评估肾功能和识别病理至关重要。推动这一市场扩张的关键因素包括全球慢性肾臟病发病率的上升以及人口老化导致肾衰竭风险增加。此外，与传统功能性检测相比，诊断准确性的提升具有重要的临床意义，这也加速了这些先进工具的应用。为了说明肾臟疾病带来的健康负担之重，国际肾臟病学会估计，到2024年，全球将有约8.5亿人患有肾臟疾病，凸显了对先进诊断解决方案的迫切需求。

儘管市场成长前景强劲，但新诊断检测方法的严格监管核准流程仍构成重大障碍。检验新型生物标记是否符合卫生监管机构制定的严格分析和临床性能标准十分复杂，往往会延缓商业化进程并增加研发成本。因此，这些监管障碍阻碍了企业进入市场，并阻碍了有前景的研究成果转化为可上市的临床解决方案，从而减缓了市场整体扩张速度。

市场驱动因素

糖尿病和高血压盛行率的不断上升是全球肾臟生物标记市场的主要驱动力。这些合併症会逐渐损害肾血管，因此迫切需要灵敏的生物标记物，以便在发生不可逆的功能衰退之前及早发现损伤。因此，医疗机构正优先考虑实施先进的诊断方案，以有效监测这些高风险患者群体。根据美国疾病管制与预防中心 (CDC) 于 2024 年 5 月发布的《美国慢性慢性肾臟病》报告，糖尿病和高血压是肾衰竭的主要原因，占所有新增病例的三分之二。这种临床负担给医疗保健系统带来了巨大的经济压力，因此亟需开发高效的诊断解决方案。为了强调这一经济驱动因素，美国国立卫生研究院 (NIH) 在其 2024 年 USRDS 年度数据报告中指出，参加 Medicare计量型支付系统的慢性肾臟病成年患者的医疗费用将在 2023 年达到 1411 亿美元。

同时，人工智慧与新型预后检测技术的融合正推动该领域迈向精准医疗。利用机器学习分析体液生物标记的先进平台，能够提供超越传统功能性检测的风险分层，使临床医生能够更准确地预测疾病进展。有利的商业性奖励进一步推动了这项技术发展。例如，Renalytics公司在2024年11月发布的「2024财年全年审核报告」中指出，其获得FDA批准的肾臟诊断测试kidneyintelX.dkd，每份可报告结果的Medicare报销高达950美元。如此高的报销额凸显了下一代诊断技术的巨大市场价值，并鼓励业界持续投资开发非侵入性、人工智慧驱动的肾臟解决方案。

市场挑战

严格的监管核准流程是肾臟生物标记领域发展的重要障碍。检验新型生物标记以满足卫生监管机构严苛的分析和临床性能标准需要耗费大量资源。这些要求显着延长了产品开发週期，并增加了整体成本。因此，企业面临更大的财务风险，降低了其投资新型诊断检测方法的意愿，并延缓了可能取代传统检测方法的工具的推出。

监管瓶颈直接限制了市场发展，限制了先进检测方法的应用，而这些方法对于弥补肾臟疾病诊断的巨大缺口至关重要。由于无法快速将有效的生物标记推向市场，目前仍依赖灵敏度低的过时检测方法，导致相当一部分患者无法及时诊断。为了说明这一诊断缺口的严重性，美国国家肾臟基金会报告称，到2024年，约90%的慢性肾臟病病患者仍将无法确诊。这项数据表明，由于新型诊断方案的监管核准延迟，市场存在巨大的未满足需求。

市场趋势

即时检测（尤其是基于智慧型手机的尿液检查）的普及，正透过分散式诊断管道重塑市场格局。这一趋势旨在解决检测普及率低的问题，尤其是在医疗资源匮乏、后勤障碍阻碍诊断的地区。在家即可进行临床级别的蛋白尿尿液检查，使医疗系统能够监测先前难以触及的高风险族群。美国国家肾臟效用在2025年8月发布的报告《消除慢性肾臟病检测中的差异》中指出，一项家庭检测倡议筛检了1496名高风险患者，其中50%的患者存在蛋白尿。这凸显了远距离诊断在发现未确诊肾臟疾病的潜力。

同时，随着新型生物标记在急性肾损伤（AKI）早期检测的应用，重症监护品质正在不断提高，这些标记取代了血清肌酸酐等延迟指标。医院正在整合能够指示功能衰竭前结构性损伤的生物标誌物，从而实现加护病房的快速干预。这种能力正在推动肾臟即时监测的发展。例如，正如2025年8月发表于BioSpace的报导「ProNephro AKI (NGAL): 一种急性肾损伤早期检测方法」中所述，BioPorto公司宣布推出一种可在48至72小时内识别中度至重度AKI风险患者的检测方法。这个快速检测窗口对于及时实施适当的保护策略至关重要。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球肾臟生物标记市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品类型（功能性生物标记、血清肌酸酐、血清胱Cystatin C、尿液白蛋白、上调蛋白、嗜中性白血球明胶酶相关脂质运载蛋白（NGAL）、肾损伤分子-1、白细胞介素-18、其他）
  • 依技术（酵素免疫分析法（ELISA）、颗粒增强浊度免疫检测（PETIA）、比色检测法、化学冷光酵素免疫分析法（CLIA）、液相层析法-质谱联用（LC-MS））
  • 依最终使用者（医院/诊所、诊断检查室、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美肾臟生物标记市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲肾臟生物标记市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区肾臟生物标记市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲肾臟生物标记市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲肾臟生物标记市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球肾臟生物标记市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Abbott Laboratories
• Beckman Coulter Inc.
• bioMerieux SA
• BioPorto A/S
• Bio-Rad Laboratories Inc.
• Enzo Biochem Inc.
• F. Hoffmann-La Roche AG
• PerkinElmer Inc.
• Randox Laboratories Ltd.
• Siemens AG
• Thermo Fisher Scientific Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Renal Biomarkers Market is projected to expand from USD 1.41 Billion in 2025 to USD 2.15 Billion by 2031, reflecting a compound annual growth rate of 7.28%. Renal biomarkers, which are measurable biological indicators detectable in blood, urine, or tissue, are essential for evaluating kidney function and identifying pathological states. The primary factors driving this market expansion include the rising global incidence of chronic kidney disease and an aging demographic that is increasingly prone to renal insufficiency. Additionally, the critical clinical need for improved diagnostic accuracy to replace traditional functional tests is accelerating the adoption of these advanced tools. To demonstrate the scale of this health burden, the International Society of Nephrology estimated in 2024 that approximately 850 million individuals worldwide were affected by kidney disease, highlighting the urgent necessity for sophisticated diagnostic solutions.

Despite this strong growth outlook, the market encounters a significant obstacle regarding the rigorous regulatory approval process for new diagnostic assays. The complexity involved in validating novel biomarkers to meet the stringent analytical and clinical performance standards set by health authorities often leads to delays in commercialization and inflated development costs. Consequently, these regulatory hurdles can discourage enterprises from entering the sector and impede the transition of promising research candidates into commercially available clinical solutions, thereby slowing the overall pace of market expansion.

Market Driver

The escalating prevalence of diabetes and hypertension serves as the primary catalyst for the Global Renal Biomarkers Market. Because these comorbidities progressively damage renal vasculature, there is a critical need for sensitive biomarkers capable of detecting early injury before irreversible decline sets in. As a result, healthcare providers are prioritizing advanced diagnostic panels to effectively monitor these high-risk patient groups. According to the Centers for Disease Control and Prevention's 'Chronic Kidney Disease in the United States' report from May 2024, diabetes and high blood pressure are the leading causes of kidney failure, accounting for two out of every three new cases. This clinical burden places immense financial strain on healthcare systems, necessitating efficient diagnostic solutions. Highlighting this economic driver, the National Institutes of Health noted in the 2024 USRDS Annual Data Report that the cost of care for adults with Medicare fee-for-service coverage and chronic kidney disease rose to $141.1 billion in 2023.

Concurrently, the integration of artificial intelligence with novel prognostic assays is propelling the sector toward precision medicine. Advanced platforms utilizing machine learning to analyze fluid biomarkers now offer risk stratification superior to traditional functional tests, enabling clinicians to predict disease progression with greater accuracy. This technological evolution is further supported by favorable commercial incentives that fuel adoption. For instance, Renalytix reported in its 'Audited Full Year Fiscal 2024 Results' in November 2024 that its FDA-authorized kidneyintelX.dkd test secured a Medicare reimbursement rate of $950 per reportable result. Such substantial reimbursement highlights the high market value of next-generation diagnostics and encourages sustained industrial investment in developing non-invasive, AI-driven renal solutions.

Market Challenge

The stringent regulatory approval process constitutes a substantial barrier to the progress of the renal biomarkers sector. Validating new biomarkers to satisfy the rigorous analytical and clinical performance standards demanded by health authorities requires extensive resources. These requirements significantly prolong the timeline for product development and increase overall expenditures. As a result, companies face heightened financial risks, which discourages investment in novel diagnostic assays and delays the introduction of tools that could replace conventional testing methods.

This regulatory bottleneck directly restricts the market by limiting the availability of advanced detection methods needed to address the massive diagnostic gap in renal care. The inability to rapidly bring effective biomarkers to market perpetuates the reliance on older, less sensitive tests, leaving a significant portion of the patient population without timely detection. To highlight the extent of this diagnostic deficit, the National Kidney Foundation reported in 2024 that approximately 90 percent of individuals with chronic kidney disease remained undiagnosed. This statistic indicates a severe market need that remains unmet due to the slow pace of regulatory clearance for new diagnostic solutions.

Market Trends

The expansion of point-of-care testing, particularly smartphone-based urinalysis, is reshaping the market by decentralizing diagnostic access. This trend addresses low adherence to laboratory screenings, especially among underserved populations where logistical barriers impede diagnosis. By enabling clinical-grade albuminuria testing at home, healthcare systems can monitor previously unreachable at-risk individuals. Validating this utility, the National Kidney Foundation reported in its August 2025 paper, 'Closing Gaps in Chronic Kidney Disease Detection', that an at-home testing initiative successfully screened 1,496 high-risk patients, with 50 percent showing evidence of albuminuria. This underscores the potential of remote diagnostics to uncover undiagnosed renal conditions.

Simultaneously, the adoption of novel biomarkers for early acute kidney injury (AKI) detection is advancing critical care by superseding lagging indicators like serum creatinine. Hospitals are integrating biomarkers that signal structural damage prior to functional loss, facilitating rapid intervention in intensive care units. This capability is driving a move toward real-time renal monitoring. For instance, as detailed in the BioSpace article 'ProNephro AKI (NGAL), early detection test for Acute Kidney Injury' from August 2025, BioPorto announced the commercial availability of a test that identifies patients at risk of moderate-to-severe AKI within 48 to 72 hours. This rapid detection window is crucial for implementing timely protective strategies.

Key Market Players

• Abbott Laboratories
• Beckman Coulter Inc.
• bioMerieux SA
• BioPorto A/S
• Bio-Rad Laboratories Inc.
• Enzo Biochem Inc.
• F. Hoffmann-La Roche AG
• PerkinElmer Inc.
• Randox Laboratories Ltd.
• Siemens AG
• Thermo Fisher Scientific Inc

Report Scope

In this report, the Global Renal Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Renal Biomarkers Market, By Product Type

• Functional Biomarker
• Serum Creatinine
• Serum Cystatin C
• Urine Albumin
• Up-regulated Protein
• Neutrophil Gelatinase-Associated Lipocalin (NGAL)
• Kidney Injury Molecule-1
• INTERLEUKIN-18
• Others

Renal Biomarkers Market, By Technique

• Enzyme-linked Immunosorbent Assay (ELISA)
• Particle-enhanced Turbidimetric Immunoassay (PETIA)
• Colorimetric Assay
• Chemiluminescent Enzyme Immunoassay (CLIA)
• Liquid Chromatography Mass Spectrometry (LC-MS)

Renal Biomarkers Market, By End user

• Hospitals & Clinics
• Diagnostic Laboratory
• Others

Renal Biomarkers Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Renal Biomarkers Market.

Available Customizations:

Global Renal Biomarkers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Renal Biomarkers Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Functional Biomarker, Serum Creatinine, Serum Cystatin C, Urine Albumin, Up-regulated Protein, Neutrophil Gelatinase-Associated Lipocalin (NGAL), Kidney Injury Molecule-1, INTERLEUKIN-18, Others)
  • 5.2.2. By Technique (Enzyme-linked Immunosorbent Assay (ELISA), Particle-enhanced Turbidimetric Immunoassay (PETIA), Colorimetric Assay, Chemiluminescent Enzyme Immunoassay (CLIA), Liquid Chromatography Mass Spectrometry (LC-MS))
  • 5.2.3. By End user (Hospitals & Clinics, Diagnostic Laboratory, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Renal Biomarkers Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Technique
  • 6.2.3. By End user
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Renal Biomarkers Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Technique
      • 6.3.1.2.3. By End user
  • 6.3.2. Canada Renal Biomarkers Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Technique
      • 6.3.2.2.3. By End user
  • 6.3.3. Mexico Renal Biomarkers Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Technique
      • 6.3.3.2.3. By End user

7. Europe Renal Biomarkers Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Technique
  • 7.2.3. By End user
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Renal Biomarkers Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Technique
      • 7.3.1.2.3. By End user
  • 7.3.2. France Renal Biomarkers Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Technique
      • 7.3.2.2.3. By End user
  • 7.3.3. United Kingdom Renal Biomarkers Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Technique
      • 7.3.3.2.3. By End user
  • 7.3.4. Italy Renal Biomarkers Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Technique
      • 7.3.4.2.3. By End user
  • 7.3.5. Spain Renal Biomarkers Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Technique
      • 7.3.5.2.3. By End user

8. Asia Pacific Renal Biomarkers Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Technique
  • 8.2.3. By End user
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Renal Biomarkers Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Technique
      • 8.3.1.2.3. By End user
  • 8.3.2. India Renal Biomarkers Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Technique
      • 8.3.2.2.3. By End user
  • 8.3.3. Japan Renal Biomarkers Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Technique
      • 8.3.3.2.3. By End user
  • 8.3.4. South Korea Renal Biomarkers Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Technique
      • 8.3.4.2.3. By End user
  • 8.3.5. Australia Renal Biomarkers Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Technique
      • 8.3.5.2.3. By End user

9. Middle East & Africa Renal Biomarkers Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Technique
  • 9.2.3. By End user
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Renal Biomarkers Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Technique
      • 9.3.1.2.3. By End user
  • 9.3.2. UAE Renal Biomarkers Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Technique
      • 9.3.2.2.3. By End user
  • 9.3.3. South Africa Renal Biomarkers Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Technique
      • 9.3.3.2.3. By End user

10. South America Renal Biomarkers Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Technique
  • 10.2.3. By End user
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Renal Biomarkers Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Technique
      • 10.3.1.2.3. By End user
  • 10.3.2. Colombia Renal Biomarkers Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Technique
      • 10.3.2.2.3. By End user
  • 10.3.3. Argentina Renal Biomarkers Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Technique
      • 10.3.3.2.3. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Renal Biomarkers Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Abbott Laboratories
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Beckman Coulter Inc.
• 15.3. bioMerieux SA
• 15.4. BioPorto A/S
• 15.5. Bio-Rad Laboratories Inc.
• 15.6. Enzo Biochem Inc.
• 15.7. F. Hoffmann-La Roche AG
• 15.8. PerkinElmer Inc.
• 15.9. Randox Laboratories Ltd.
• 15.10. Siemens AG
• 15.11. Thermo Fisher Scientific Inc

16. Strategic Recommendations

17. About Us & Disclaimer